The breast cancer drug Lynparza (olaparib) has shown promising results in a phase III trial comparing it with standard breast cancer treatment, AstraZeneca announced recently.
AstraZeneca said patients given the Lynparza tablets a showed a "statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) compared with those who received chemotherapy."
“These results are positive news for patients with BRCA-mutated metastatic breast cancer, a disease with a high unmet need, and are the first positive phase III data for a PARP inhibitor beyond ovarian cancer," Sean Bohen, executive vice president of AstraZeneca's Global Medicines Development, said.
Patients were given the Lynparza tablets twice a day. A full evaluation of the data is ongoing and the results will be submitted for presentation at a forthcoming medical meeting.
